SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics


Today's Latest Price: $57.99 USD

1.49 (-2.51%)

Updated Oct 30 4:00pm

Add SWTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

SWTX Stock Price Chart Interactive Chart >

Price chart for SWTX

SWTX Price/Volume Stats

Current price $57.99 52-week high $63.31
Prev. close $59.48 52-week low $17.02
Day low $57.00 Volume 193,200
Day high $59.90 Avg. volume 202,627
50-day MA $49.92 Dividend yield N/A
200-day MA $39.19 Market Cap 2.49B


Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

SWTX Latest News Stream

Event/Time News Detail
Loading, please wait...

SWTX Latest Social Stream

Loading social stream, please wait...

View Full SWTX Social Stream

Latest SWTX News From Around the Web

Below are the latest news stories about SpringWorks Therapeutics Inc that investors may wish to consider to help them evaluate SWTX as an investment opportunity.

SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

STAMFORD, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on…

GlobeNewswire | September 22, 2020

SpringWorks inks deal for nirogacestat in rare soft-tissue tumors

SpringWorks Therapeutics (SWTX) enters into a sponsored research agreement with Fred Hutchinson Cancer Research Center to further evaluate nirogacestat to modulate B-cell maturation antigen and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch.Nirogacestat is an investigational, oral,...

Seeking Alpha | September 18, 2020

SpringWorks teams up with COG for nirogacestat in pediatric patients with soft tissue tumors

SpringWorks Therapeutics (SWTX) collaborates with the Children’s Oncology Group ((COG)) to evaluate nirogacestat, an investigational gamma secretase inhibitor, in a Phase 2 clinical trial for the treatment of children and adolescents with progressive, surgically unresectable desmoid tumors, which are rare and often debilitating soft tissue tumors that can cause severe...

Seeking Alpha | September 16, 2020

SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors

STAMFORD, Conn., July 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on…

GlobeNewswire | July 22, 2020

Hedge Funds Keep Buying SpringWorks Therapeutics, Inc. (SWTX)

In this article we will take a look at whether hedge funds think SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 28, 2020

Read More 'SWTX' Stories Here

SWTX Price Returns

1-mo 21.65%
3-mo 36.03%
6-mo 91.96%
1-year 203.61%
3-year N/A
5-year N/A
YTD 50.66%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6401 seconds.